Loading...
•
Mar 31, 2022
Intra-Cellular Q1 2022 Earnings Report
Intra-Cellular Therapies experienced a strong launch of CAPLYTA® in bipolar depression, with significant increases in prescriptions and revenue.
Key Takeaways
Intra-Cellular Therapies reported a total revenue of $35 million for Q1 2022, a 120% increase compared to Q1 2021. CAPLYTA net product revenues were $34.8 million, representing a 123% increase year-over-year. The company's net loss was $72.1 million, and cash, cash equivalents, and investment securities totaled $773.2 million.
Total revenues for Q1 2022 were $35.0 million, a 120% increase compared to $15.9 million in Q1 2021.
CAPLYTA net product revenues were $34.8 million for Q1 2022, a 123% increase compared to $15.6 million for the same period in 2021.
CAPLYTA new and total prescriptions increased 63% and 45%, respectively, versus the fourth quarter 2021.
Net loss for the quarter ended March 31, 2022, was $72.1 million, compared to a net loss of $52.7 million for the quarter ended March 31, 2021.
Forward Guidance
Intra-Cellular Therapies anticipates continued strong growth of CAPLYTA and is advancing its pipeline, including lumateperone programs in MDD and mixed features.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...